Next-generation genetic sequencing (NGS) will have a profound impact on the healthcare landscape. Within the foreseeable future, NGS will be cost-effective and readily available to large patient groups - we can even envisage most citizens having their exome sequenced in post-natal screening programmes. What impact will this have on the practice of healthcare and on the private sector? We investigate.